The company that bet a whole pipeline on one overlooked protein - Claudin-1 - and its strange habit of showing up in both scar tissue and tumors.
Most drug companies hedge. They keep three diseases in mind, four mechanisms in a drawer, and a slide that says "platform" so investors feel safe. Alentis Therapeutics did the opposite. It picked one molecule - Claudin-1 - and built everything around it. The website does not bury the lede. It just says: The Claudin-1 Company.
Today Alentis is a clinical-stage biotech of roughly 68 people, headquartered in Allschwil on the edge of Basel, with research roots in Strasbourg. It has raised around $365 million, the bulk of it in an oversubscribed $181.4 million Series D in late 2024. Three drug candidates are in trials. A new CEO arrived in October 2025 specifically to steer the company through the year its data either works or it doesn't.
That is the bet. Claudin-1 is not glamorous. It is a tight-junction protein, the molecular glue that seals cells together so tissues hold their shape. For decades it was a footnote. Alentis turned the footnote into a business plan.
Fibrosis is what happens when the body's repair crew never clocks out. A kidney, a liver, a lung gets injured, lays down scar tissue to patch it, and then keeps laying it down until the organ stiffens and quits. There are very few good drugs for it. The conventional wisdom said scar tissue was permanent - you manage the decline, you do not undo it.
Cancer is the other half. Solid tumors hide behind their own architecture, and chemotherapy that kills tumor cells tends to kill healthy ones on the way. Oncologists have spent a generation looking for a flag that sits on the tumor and almost nowhere else - something a drug could aim at without scorching the patient.
Here is the quiet trick of Claudin-1. In healthy tissue it is tucked away inside cell junctions, invisible to the bloodstream. But when tissue turns fibrotic or cancerous, the protein gets exposed - shoved out where an antibody can reach it. So a drug aimed at exposed Claudin-1 mostly ignores healthy cells and finds the diseased ones. Same target, two diseases, and a built-in way to tell sick tissue from well.
The science did not start in a boardroom. It started with Professor Thomas Baumert, a physician-scientist at the University of Strasbourg and Inserm, who first ran into Claudin-1 while studying how the hepatitis C virus breaks into liver cells. The protein turned out to be one of the virus's entry points. That was the thread he kept pulling.
More than fifteen years of work later, Baumert's teams had an anti-Claudin-1 antibody and a growing pile of evidence that the target mattered far beyond hepatitis. In 2019 that body of research became Alentis Therapeutics. In 2023 Baumert was awarded the INSERM Research Prize for the underlying science. The company is, in a real sense, an academic hunch that refused to die.
The leadership has since been built for the clinic. Roberto Iacone, who had helped build Black Diamond Therapeutics and run rare-disease research at Roche, served as CEO from 2020 and carried the company from discovery to a well-funded pipeline. In October 2025, Mark Pruzanski - the founder of Intercept Pharmaceuticals, who once took a liver-disease drug from lab bench to market - took over as CEO for the next, harder act.
Alentis split its single target into two kinds of weapon. For fibrosis, a plain antibody that blocks Claudin-1's signaling and lets the body stop scarring. For cancer, an antibody-drug conjugate - an ADC - which is an antibody with a cancer-killing payload bolted on, designed to dump that payload only where it finds exposed Claudin-1.
The lead drug for organ fibrosis - kidney, liver and lung - plus ANCA-associated vasculitis. Aims not just to slow scarring but to reverse it.
Phase 1/2 · Orphan Drug in IPFA first-in-class CLDN1 ADC aimed at squamous solid tumors, including head and neck cancers. Delivers its payload into tumor tissue while sparing healthy cells.
Phase 1/2 · FDA Fast TrackA second CLDN1 ADC for solid tumors, broadening the oncology reach of the platform into first-in-human testing.
Phase 1 · First-in-humanFounded on Thomas Baumert's anti-Claudin-1 discovery from Strasbourg and Inserm, backed by Versant Ventures and others.
A physician-entrepreneur takes the helm to push from discovery toward the clinic.
Capital to advance Claudin-1 medicines across fibrosis and oncology.
Founder honored; preclinical data for Claudin-1 antibodies appear in Science Translational Medicine.
Oversubscribed round co-led by OrbiMed, Novo Holdings and Jeito. ALE.P02 wins Fast Track; lixudebart gets Orphan Drug status in IPF.
The Intercept founder arrives ahead of key clinical readouts expected across all three candidates.
Skeptics are right to ask whether a one-target story holds up. The clearest external vote came in November 2024, when Alentis closed a $181.4 million Series D that was oversubscribed - more investors wanted in than there was room for. It was co-led by OrbiMed, Novo Holdings and Jeito Capital, with Frazier, Longitude, RA Capital, Catalio and others crowding the cap table.
Regulators leaned in too. The FDA cleared ALE.P02 to enter human trials and gave it Fast Track designation for squamous cancers; it granted lixudebart Orphan Drug status in idiopathic pulmonary fibrosis. Neither is approval. Both are the kind of signal that says the agency thinks the question is worth answering.
Alentis states its mission in four words: treat cancer and reverse fibrosis. The verb that does the heavy lifting is "reverse." Most fibrosis drugs aim to slow the decline. Alentis is testing whether scarred tissue can actually heal - whether a stiffened kidney or a fibrotic lung can be coaxed back toward function rather than simply held in place.
The patients on the other end of this are not abstract. People on dialysis paths from kidney fibrosis. People with idiopathic pulmonary fibrosis, who today face a grim clock. People with ANCA-associated vasculitis, and patients with squamous tumors who have run out of gentle options. The mission is plain because the stakes are.
Here is the honest part. A focused thesis is a beautiful thing right up until the data arrives. Alentis has spent six years and hundreds of millions building toward clinical readouts that will, fairly bluntly, tell the world whether Claudin-1 was a brilliant insight or an expensive one. The new CEO said it out loud: key data for all three candidates is expected in the near term.
If it works, the payoff is unusually broad - one biology that could touch fibrosis across three organs and cancer across multiple tumor types. That is the upside of refusing to hedge. Now return to that lab shelf and the row of vials. When the company started, Claudin-1 was a protein most of the field walked past. Today it has a clinical pipeline, a fresh CEO built for the home stretch, and a roomful of investors waiting on the same answer. The vials have not changed. What they might prove has.